Likitanci da magunguna · Bayanan hukuma
EMA ta ba da shawarar amincewa da Baxfendy (baxdrostat) don hawan jini
Kwamitin CHMP na EMA ya amince da ra'ayi mai kyau a ranar 12 ga Nuwamba 2026 yana ba da shawarar izinin tallace-tallace don Baxfendy (baxdrostat), wanda AstraZeneca AB ta haɓaka. Wannan magani mai dauke da baxdrostat an nuna shi don magance marasa lafiya da ke da hawan jini na arterial hypertension. Yana gabatar da sabon tsari don sarrafa hawan jini.
Asalin tushe
Karanta tushen — ema.europa.eu ↗Muna haɗawa da ainihin mai wallafawa. Taƙaitawar da ke sama jagora ce kawai; karanta asalin don cikakken bayani.